Argenx cans Phase III Vyvgart Sjögren’s study on predicted efficacy fail
Argenx halted a Phase III trial for Vyvgart in Sjögren’s syndrome due to predicted efficacy failure. Novartis' ianalumab and Amgen's dazodalibep have shown positive Phase III results in the same condition. Vor Bio and RemeGen's telitacicept also showed promise in a Chinese study.
How this was made
The 30-second read
Why it matters
The announcement is a primary disclosure of a negative clinical outcome, which typically leads to a sharp decline in the stock price of the affected biotech firm.
Market read
Argenx’s trial failure is likely to depress its share price and may influence sentiment toward other biotech firms pursuing autoimmune therapies.
What to watch
Trial design nuances and potential for later data read‑outs could mitigate the impact.
Background
Argenx (ARX) announced the cancellation of its Phase III Vyvgart trial for Sjögren’s syndrome after a predicted efficacy failure, joining other companies reporting mixed results in the autoimmune space.
Market effects
Setback for Sjögren’s syndrome therapeutic pipeline and may dampen investor appetite for similar biotech programs.
US biotech equities could see modest downside pressure.
Limited to biotech sector; no broad market effect.
Counterpoint
If the company can pivot the asset to another indication, the stock may recover.
Key entities
- companyArgenx
US‑listed biotech developing Vyvgart for Sjögren’s syndrome.
- companyNovartis
Mentioned as a peer with successful Phase III trials in the same indication.
- companyAmgen
Peer also conducting Phase III trials for Sjögren’s syndrome.
